Cytek BioSciences Inc Forecast, price target & analysts
Cytek BioSciences Inc Target price 2025 - Analyst rating & recommendation
Cytek BioSciences Inc Classifications & Recommendation:
Cytek BioSciences Inc Price Target
| Target Price | $5.61 |
| Price | $3.55 |
| Potential |
58.03%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Cytek BioSciences Inc 2026 .
The average Cytek BioSciences Inc target price is $5.61.
This is
58.03%
register free of charge
$8.40
136.62%
register free of charge
$4.04
13.80%
register free of charge
|
|
| A rating was issued by 12 analysts: 7 Analysts recommend Cytek BioSciences Inc to buy, 4 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cytek BioSciences Inc stock has an average upside potential 2026 of
58.03%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 200.45 | 202.27 |
| 3.85% | 0.91% | |
| EBITDA Margin | -5.00% | 8.19% |
| 48.13% | 263.68% | |
| Net Margin | -3.00% | -14.00% |
| 52.29% | 366.16% |
7 Analysts have issued a sales forecast Cytek BioSciences Inc 2025 . The average Cytek BioSciences Inc sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Cytek BioSciences Inc EBITDA forecast 2025. The average Cytek BioSciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Cytek BioSciences Inc Analysts have issued a net profit forecast 2025. The average Cytek BioSciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.05 | -0.22 |
| 44.44% | 340.00% | |
| P/E | negative | |
| EV/Sales | 0.93 |
7 Analysts have issued a Cytek BioSciences Inc forecast for earnings per share. The average Cytek BioSciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Cytek BioSciences Inc...
Current Cytek BioSciences Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 28 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 28 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 11 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
